Table 2 Adverse reactions of included studies
Adverse reactions | Control group (cases/toal paitents) | Experimental group (cases/toal paitents) | Heterogeneity test | RR(95%CI) | p | |
|---|---|---|---|---|---|---|
I 2 | P | |||||
Abnormal liver function | 66/608 | 64/739 | 0 | 0.82 | 0.90(0.67 ~ 1.20) | 0.46 |
Sepsis | 207/420 | 242/547 | 6% | 0.36 | 0.94(0.82 ~ 1.07) | 0.36 |
Necrotizing enterocolitis | 43/420 | 46/547 | 0 | 0.60 | 0.90(0.60 ~ 1.34) | 0.60 |
Bronchopulmonary dysplasia | 135/370 | 164/497 | 55% | 0.11 | 0.99(0.84 ~ 1.17) | 0.93 |
Patent ductus arteriosus | 61/329 | 83/454 | 4% | 0.35 | 1.03(0.75 ~ 1.42) | 0.86 |
Retinopathy of prematurity | 72/420 | 84/547 | 28% | 0.24 | 0.91(0.64 ~ 1.29) | 0.60 |